sabirnetug — Topline data
late 2026
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Source filing
ABOS biotech catalysts & pipeline
ACUMEN PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
ACU301 — IND submission
mid-2027
Based on these developments, an investigational new drug, or IND, application for the lead candidate is targeted for mid-2027.Source filing
ACU301 and ACU401 — IND submission
mid-2027
Investigational New Drug (IND)-enabling activities are ongoing to support IND submission in mid-2027Source filing
Acumen's Enhanced Brain Delivery (EBD TM ) program — IND submission
mid-2027
• Lead clinical candidate IND filing in Acumen's Enhanced Brain Delivery (EBD TM ) program targeted for mid-2027, following strong preclinical data and $35.75 million private placement to advance candidates in AβO-selective EBD portfolioSource filing
EBD program lead clinical candidate — IND submission
mid-2027
Two candidates nominated for development in Acumen's Enhanced Brain Delivery™ (EBD™) program; lead clinical candidate IND filing for the EBD program targeted for mid-2027Source filing
Enhanced Brain Delivery (EBD) candidates — IND submission
mid-2027
Based on this data, an investigational new drug, or IND, application is targeted for mid-2027.Source filing